Semaglutide vs Tirzepatide vs Retatrutide: A Doctor's Guide for Thailand

Semaglutide, tirzepatide and retatrutide are the three most discussed GLP-1 class medications for physician-supervised weight loss in Thailand right now. They are not the same: each acts on a different number of metabolic receptors, has its own trial data and comes with its own clinical requirements. This guide explains the differences clearly so you can have an informed conversation with your doctor.

Overview Comparison

These are controlled-trial averages from separate studies, not direct head-to-head comparisons. Individual results vary based on starting weight, adherence, dose reached and other factors.

Semaglutide: The Established GLP-1

Semaglutide is the active ingredient in Ozempic and Wegovy. It is the most widely studied GLP-1 receptor agonist for weight loss, with a substantial body of randomized controlled trial data and long-term follow-up.

How it works

Semaglutide binds to the GLP-1 receptor, which slows gastric emptying, increases satiety signaling to the brain and reduces appetite. At therapeutic doses used for weight management, the effect on appetite is the dominant mechanism.

Trial data highlights

The STEP trial program showed average weight loss of around 15 percent of body weight at 68 weeks in adults without diabetes, using the 2.4 mg weekly dose. Results in people with type 2 diabetes were somewhat lower.

Who it suits

Semaglutide is usually the first-line GLP-1 option for patients new to this class of medication. It is well characterized, widely available in Thailand as a compounded clinical-grade product, and most physicians are experienced with its titration schedule.

What to watch for

Nausea is common early on and at dose increases. Titrating slowly reduces this significantly. Pancreatitis history and certain thyroid conditions are contraindications your doctor will screen for.

Tirzepatide: Dual Agonist with Stronger Average Results

Tirzepatide is the active ingredient in Mounjaro. It acts on two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The GIP component changes how fat tissue responds to insulin and may amplify the weight-loss effect beyond semaglutide alone.

How it works

The dual mechanism gives tirzepatide two complementary pathways. GLP-1 activity reduces appetite and slows digestion. GIP activity improves how fat tissue handles energy and supports insulin sensitivity. The combined effect on weight loss has been consistently stronger than semaglutide in trials.

Trial data highlights

The SURMOUNT trial program showed average weight loss of around 20 to 22 percent of body weight at 72 weeks on the highest dose, in adults without diabetes. This is the highest average figure in an approved weight-loss medication.

Who it suits

Tirzepatide is a good option for patients who want the additional data behind a dual-agonist, or for those who have reached a plateau on semaglutide. It is available in Thailand as a clinical-grade compounded product under physician supervision.

What to watch for

Similar side-effect profile to semaglutide: nausea, digestive changes and occasional fatigue, especially early in treatment. The same contraindications apply.

Retatrutide: Triple Agonist, Still Investigational

Retatrutide adds a third receptor: glucagon. Glucagon normally raises blood sugar and increases energy expenditure. In the context of a triple agonist, researchers believe the glucagon component drives additional fat breakdown in the liver and raises resting energy use, contributing to the stronger weight-loss signal seen in phase 2 trials.

How it works

By activating GLP-1, GIP and glucagon receptors simultaneously, retatrutide targets three metabolic pathways at once. The glucagon mechanism is what separates it from tirzepatide, and also why blood glucose and heart rate need more careful monitoring during treatment.

Trial data highlights

A 2023 phase 2 trial published in the New England Journal of Medicine showed average weight loss of around 24 percent of body weight at 48 weeks on the highest dose. This is a single trial at phase 2 level. Phase 3 trials are ongoing and regulatory approval has not yet been granted in Thailand or elsewhere.

Who it suits

Retatrutide is assessed on a case-by-case basis. It may be considered for patients who have not reached their goals on semaglutide or tirzepatide, or who are specifically asking about next-generation options. Availability is limited and physician oversight is more intensive given the glucagon mechanism.

What to watch for

All the side effects of GLP-1 medications apply, plus closer monitoring of heart rate and blood glucose because of the glucagon receptor activity. This is not a self-start medication.

For full details, read the dedicated Retatrutide in Thailand guide.

Which One Is Right for You?

That is a question for your doctor, not a website. The right choice depends on your health history, current medications, starting weight, goals and how you respond to titration. What this comparison can do is help you understand what to ask.

A few practical notes:

• Semaglutide and tirzepatide are both well-established and widely available in Thailand with a prescription. Either can be a sensible starting point.
• Tirzepatide has shown stronger average results in trials and is worth discussing if you want the dual-agonist data behind your program.
• Retatrutide is the most powerful option by trial data, but it remains investigational and requires closer clinical oversight.
• All three require a proper medical screening, a supervised titration schedule and ongoing follow-up. None should be self-administered from an online source.

Doctor-Supervised Programs in Thailand

Peptides Thailand offers physician-supervised GLP-1 weight loss programs in Bangkok, Phuket and Chiang Mai, with clinical-grade medication from licensed Thai compounding laboratories. Every batch comes with a Certificate of Analysis.

• Weight Loss Bangkok - Fully online, delivery across the city
• Weight Loss Phuket - Programs for expats and medical tourists
• Weight Loss Chiang Mai - In-person or video consultation

For a broader look at peptides studied for fat loss, visit the fat loss peptides overview.